Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DOSCORT dose-response study of glucocorticoid biomarkers in Addison's disease
2016-004078-16Phase 4Completed
- Sponsor
- Sahlgrenska University Hospital
- Start
- May 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of betamethasone in Addison's disease (2 arms), sponsored by Sahlgrenska University Hospital. Primary endpoint: Change in plasma miR-122 expression between doses. Started May 2017; status: completed.
02
Drugs
betamethasone
03
Conditions
Addison's disease
Beyond the preview
Go deeper on 2016-004078-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004078-16.